Lars Neumann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lars neumann. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lars Neumann Today - Breaking & Trending Today

Surgery, Chemotherapy Considered Protective Survival Factors in Patients With OC, Liver Metastases

Surgery and chemotherapy significantly improved both overall survival (OS) and cancer-specific survival (CSS) in patients with liver metastases originating from ovarian cancer (OC), who generally face a poor prognosis with a 5-year survival rate of less than 30%. ....

Lars Neumann , International Classification Of Diseases , Image Credit , End Results , International Classification , Clin Exp ,

Metal Ion Chelators Hold Enormous Potential in Neurodegenerative Disorders

Monitoring metal ion concentrations and chelation therapy is hypothesized to alleviate symptoms and diseases caused by neuroinflammation. ....

Ramos Escobarn Neuroinflammation , Lars Neumann , Aducanumab Aduhelm , Ion Chelators , Neurodegerative Disease , Are They , Rev Drug ,

Blood Type and Health

Does your blood type play a role in your risk for disease? Find out how it fares in the face of certain conditions. ....

United States , Andreypopov Thinkstock , Lars Neumann Getty , Eraxion Thinkstock , Journal Of The National Cancer Institute , Blood Group System , University Of Wisconsin Health , Blood Group , American Cancer Society , Heart Health , Your Blood Type Mean For Health , International Journal Of Molecular Sciences , Lars Neumann , Vascular Biology , Coronary Heart Disease , Two Prospective Cohort Studies , Golestan Cohort Study , Cancer Society , Cancer Risk Factors , Wisconsin Health , Type Test , National Cancer Institute , Pancreatic Cancer , Case Control Study , Does Your Blood Type Mean , Interdisciplinary Reviews ,

Triplet Maintenance Therapy Effective in Platinum-Sensitive Recurrent Ovarian Cancer

Results from the OPEB-01/APGOT-OV4 trial highlight the potential benefits of using olaparib, pembrolizumab, and bevacizumab as a triplet maintenance therapy for patients who have responded to chemotherapy after experiencing platinum-sensitive recurrence in ovarian cancer. ....

Lars Neumann , Nature Communications , Image Credit , Ovarian Cancer , Platinum Sensitive , Opeb 01 Apgot Ov4 ,

PARP Inhibition Changes Individualized Treatment in Advanced Ovarian Cancer

The addition of PARP inhibitors for the treatment of patients with BRCA-mutated advanced ovarian cancer has provided clinicians with a stronger set of treatment options. Looking at how the BRCA mutation responds to these inhibitors is then vital to deciding the patient’s treatment path. ....

United States , New Orleans , Dilip Solanki , Lars Neumann , Los Angeles , End Results Program , National Cancer Institute , American Society Of Clinical Oncology , Genomics Education Programme , National Cancer Institute Surveillance , American Cancer Society , Ochsner Cancer Institute , University Of California , American Cancer , American Society , Clinical Oncology , Ritu Salani , Case Based Roundtable , Texas Oncology , Medical Oncology Gynaecological Cancers Congress , Updated January , Statistics Review , Cancer Institute Surveillance , End Results , Updated November , Epidemiol Biomarkers ,